197 related articles for article (PubMed ID: 35502563)
1. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States.
Sheshadri A; Sacks NC; Healey B; Cyr P; Boerner G; Huang HJ
J Med Econ; 2022; 25(1):650-659. PubMed ID: 35502563
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States.
Sacks NC; Healey BE; Raza S; Cyr PL; Boerner G; Sheshadri A
Blood Adv; 2022 Mar; 6(5):1566-1576. PubMed ID: 34807973
[TBL] [Abstract][Full Text] [Related]
3. Chronic Lung Allograft Dysfunction Is Associated with Significant Disability after Lung Transplantation-A Burden of Disease Analysis in 1025 Cases.
Diel R; Simon S; Gottlieb J
Adv Respir Med; 2023 Oct; 91(5):432-444. PubMed ID: 37887076
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.
Leuschner G; Lauseker M; Howanietz AS; Milger K; Veit T; Munker D; Schneider C; Weig T; Michel S; Barton J; Meiser B; Dinkel J; Neurohr C; Behr J; Kneidinger N
J Heart Lung Transplant; 2020 Nov; 39(11):1270-1278. PubMed ID: 32917480
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction.
Todd JL; Neely ML; Finlen Copeland CA; Frankel CW; Reynolds JM; Palmer SM
J Heart Lung Transplant; 2019 Feb; 38(2):184-193. PubMed ID: 30466803
[TBL] [Abstract][Full Text] [Related]
6. Percentage of low attenuation area on computed tomography detects chronic lung allograft dysfunction, especially bronchiolitis obliterans syndrome, after bilateral lung transplantation.
Kubo Y; Sugimoto S; Shiotani T; Matsubara K; Hashimoto K; Tanaka S; Shien K; Suzawa K; Miyoshi K; Yamamoto H; Okazaki M; Toyooka S
Clin Transplant; 2023 Nov; 37(11):e15077. PubMed ID: 37461238
[TBL] [Abstract][Full Text] [Related]
7. Validation of a post-transplant chronic lung allograft dysfunction classification system.
Van Herck A; Verleden SE; Sacreas A; Heigl T; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck D; Verleden GM; Vos R
J Heart Lung Transplant; 2019 Feb; 38(2):166-173. PubMed ID: 30391199
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
9. Lung Function Monitoring After Lung Transplantation and Allogeneic Hematopoietic Stem Cell Transplantation.
Sheshadri A; Sacks NC; Healey BE; Raza S; Boerner G; Huang HJ
Clin Ther; 2022 May; 44(5):755-765.e6. PubMed ID: 35513911
[TBL] [Abstract][Full Text] [Related]
10. Primary graft dysfunction grade 3 following pediatric lung transplantation is associated with chronic lung allograft dysfunction.
Wong W; Johnson B; Cheng PC; Josephson MB; Maeda K; Berg RA; Kawut SM; Harhay MO; Goldfarb SB; Yehya N; Himebauch AS
J Heart Lung Transplant; 2023 May; 42(5):669-678. PubMed ID: 36639317
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA.
Hagiwara M; Divino V; Munnangi S; Delegge M; Park S; Marins EG; Ren K; Strange C
J Comp Eff Res; 2024 Jun; 13(6):e230186. PubMed ID: 38696696
[No Abstract] [Full Text] [Related]
12. Low-dose computed tomography volumetry for subtyping chronic lung allograft dysfunction.
Saito T; Horie M; Sato M; Nakajima D; Shoushtarizadeh H; Binnie M; Azad S; Hwang DM; Machuca TN; Waddell TK; Singer LG; Cypel M; Liu M; Paul NS; Keshavjee S
J Heart Lung Transplant; 2016 Jan; 35(1):59-66. PubMed ID: 26342441
[TBL] [Abstract][Full Text] [Related]
13. Phenotyping CLAD after single lung transplant: Limits and prognostic assessment of the 2019 ISHLT classification system.
Berra G; Huszti E; Levy L; Kawashima M; Fuchs E; Renaud-Picard B; Riddell P; Dias O; Rajagopala S; Ulahannan A; Ghany R; Singer LG; Tikkanen J; Martinu T
J Heart Lung Transplant; 2022 May; 41(5):599-607. PubMed ID: 35351385
[TBL] [Abstract][Full Text] [Related]
14. Fungal infection and colonization in lung transplant recipients with chronic lung allograft dysfunction.
Pennington KM; Aversa M; Martinu T; Johnson B; Husain S
Transpl Infect Dis; 2022 Dec; 24(6):e13986. PubMed ID: 36380578
[TBL] [Abstract][Full Text] [Related]
15. Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience.
Sugimoto S; Yamamoto H; Kurosaki T; Otani S; Okazaki M; Yamane M; Toyooka S; Oto T
Surg Today; 2019 Aug; 49(8):686-693. PubMed ID: 30790054
[TBL] [Abstract][Full Text] [Related]
16. Montelukast in chronic lung allograft dysfunction after lung transplantation.
Vos R; Eynde RV; Ruttens D; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck DE; Verleden GM;
J Heart Lung Transplant; 2019 May; 38(5):516-527. PubMed ID: 30638839
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment of chronic lung allograft dysfunction phenotypes: Validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system.
Levy L; Huszti E; Renaud-Picard B; Berra G; Kawashima M; Takahagi A; Fuchs E; Ghany R; Moshkelgosha S; Keshavjee S; Singer LG; Tikkanen J; Martinu T
J Heart Lung Transplant; 2020 Aug; 39(8):761-770. PubMed ID: 32418864
[TBL] [Abstract][Full Text] [Related]
19. Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.
Kulkarni HS; Cherikh WS; Chambers DC; Garcia VC; Hachem RR; Kreisel D; Puri V; Kozower BD; Byers DE; Witt CA; Alexander-Brett J; Aguilar PR; Tague LK; Furuya Y; Patterson GA; Trulock EP; Yusen RD
J Heart Lung Transplant; 2019 Jan; 38(1):5-16. PubMed ID: 30391193
[TBL] [Abstract][Full Text] [Related]
20. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
